During the past decade, UNC Dermatology and Skin Cancer Center conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 7 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UNC Dermatology and Skin Cancer Center" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Castle Creek Pharmaceuticals, LLC" with 1 trials sponsored, "Dermtreat" with 1 trials sponsored, "Edesa Biotech Inc." with 1 trials sponsored and "Galderma R&D" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UNC Dermatology and Skin Cancer Center" #1 collaborator was "Incyte Corporation" with 1 trials as a collaborator, "JSS Medical Research Inc." with 1 trials as a collaborator, "Proinnovera GmbH" with 1 trials as a collaborator and "X-act Cologne Clinical Research GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "UNC Dermatology and Skin Cancer Center" are "Plaque Psoriasis" (3 trials), "Psoriasis" (3 trials), "Alopecia Areata" (2 trials), "Atopic Dermatitis" (2 trials) and "Allergic Contact Dermatitis" (1 trials). Many other conditions were trialed in "UNC Dermatology and Skin Cancer Center" in a lesser frequency.

Most popular intervention types in "UNC Dermatology and Skin Cancer Center" are "Drug" (11 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Ixekizumab" (2 trials), "Mirikizumab" (2 trials), "Asimadoline" (1 trials) and "Baricitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "UNC Dermatology and Skin Cancer Center" are 12 trials for "All" genders.

Currently, there are NaN active trials in "UNC Dermatology and Skin Cancer Center". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in UNC Dermatology and Skin Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UNC Dermatology and Skin Cancer Center, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".